Cargando…
The new Veterinary Medicines Regulation: rising to the challenge
This article focuses on the new Veterinary Medicines Regulation, which is applicable across all Member States of the European Union, including Ireland, from 28 January 2022. From this date, prophylactic use of antimicrobials (AMs) in groups of animals is banned, metaphylactic use in groups of animal...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812186/ https://www.ncbi.nlm.nih.gov/pubmed/35115047 http://dx.doi.org/10.1186/s13620-022-00209-6 |
_version_ | 1784644596208238592 |
---|---|
author | More, Simon J. McCoy, Finola McAloon, Catherine I. |
author_facet | More, Simon J. McCoy, Finola McAloon, Catherine I. |
author_sort | More, Simon J. |
collection | PubMed |
description | This article focuses on the new Veterinary Medicines Regulation, which is applicable across all Member States of the European Union, including Ireland, from 28 January 2022. From this date, prophylactic use of antimicrobials (AMs) in groups of animals is banned, metaphylactic use in groups of animals is restricted, and certain AMs are reserved for humans only. In the Irish dairy industry, as elsewhere, successful implementation of the Regulation will require a high level of mastitis control across all herds, and measures to support high standards in antibiotic stewardship. National actions will be critical, to support optimal mastitis control throughout the national herd. For private veterinary practitioners (PVPs), the Regulation will lead to specific prescribing changes, including the requirement to shift from blanket to selective dry cow therapy. Further, prescribing choices will need to be guided by the categorisation for AMs developed by the European Medicines Agency (EMA). More broadly, the Regulation requires a fundamental shift in thinking both in terms of AM usage and of the role of the PVP. Given the close association between mastitis control and intramammary AM stewardship, it is imperative that prescribing and mastitis control decisions are made concurrently. A herd health approach will be critical, within a Client-Patient-Practice Relationship as outlined by the Veterinary Council of Ireland. On those farms with sub-optimal mastitis control, mastitis issues need to be sustainably resolved. A detailed farm investigation by the PVP, in partnership with the farmer and other milk quality professionals, is essential, to understand the epidemiology and on-farm drivers of mastitis, to develop farm-specific action plans, and to facilitate ongoing monitoring of progress. It is vital that PVPs provide leadership, with the provision of a holistic, herd health approach to inform both prescribing and mastitis control decisions in herds under their care. |
format | Online Article Text |
id | pubmed-8812186 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88121862022-02-03 The new Veterinary Medicines Regulation: rising to the challenge More, Simon J. McCoy, Finola McAloon, Catherine I. Ir Vet J Commentary This article focuses on the new Veterinary Medicines Regulation, which is applicable across all Member States of the European Union, including Ireland, from 28 January 2022. From this date, prophylactic use of antimicrobials (AMs) in groups of animals is banned, metaphylactic use in groups of animals is restricted, and certain AMs are reserved for humans only. In the Irish dairy industry, as elsewhere, successful implementation of the Regulation will require a high level of mastitis control across all herds, and measures to support high standards in antibiotic stewardship. National actions will be critical, to support optimal mastitis control throughout the national herd. For private veterinary practitioners (PVPs), the Regulation will lead to specific prescribing changes, including the requirement to shift from blanket to selective dry cow therapy. Further, prescribing choices will need to be guided by the categorisation for AMs developed by the European Medicines Agency (EMA). More broadly, the Regulation requires a fundamental shift in thinking both in terms of AM usage and of the role of the PVP. Given the close association between mastitis control and intramammary AM stewardship, it is imperative that prescribing and mastitis control decisions are made concurrently. A herd health approach will be critical, within a Client-Patient-Practice Relationship as outlined by the Veterinary Council of Ireland. On those farms with sub-optimal mastitis control, mastitis issues need to be sustainably resolved. A detailed farm investigation by the PVP, in partnership with the farmer and other milk quality professionals, is essential, to understand the epidemiology and on-farm drivers of mastitis, to develop farm-specific action plans, and to facilitate ongoing monitoring of progress. It is vital that PVPs provide leadership, with the provision of a holistic, herd health approach to inform both prescribing and mastitis control decisions in herds under their care. BioMed Central 2022-02-03 /pmc/articles/PMC8812186/ /pubmed/35115047 http://dx.doi.org/10.1186/s13620-022-00209-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Commentary More, Simon J. McCoy, Finola McAloon, Catherine I. The new Veterinary Medicines Regulation: rising to the challenge |
title | The new Veterinary Medicines Regulation: rising to the challenge |
title_full | The new Veterinary Medicines Regulation: rising to the challenge |
title_fullStr | The new Veterinary Medicines Regulation: rising to the challenge |
title_full_unstemmed | The new Veterinary Medicines Regulation: rising to the challenge |
title_short | The new Veterinary Medicines Regulation: rising to the challenge |
title_sort | new veterinary medicines regulation: rising to the challenge |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812186/ https://www.ncbi.nlm.nih.gov/pubmed/35115047 http://dx.doi.org/10.1186/s13620-022-00209-6 |
work_keys_str_mv | AT moresimonj thenewveterinarymedicinesregulationrisingtothechallenge AT mccoyfinola thenewveterinarymedicinesregulationrisingtothechallenge AT mcalooncatherinei thenewveterinarymedicinesregulationrisingtothechallenge AT moresimonj newveterinarymedicinesregulationrisingtothechallenge AT mccoyfinola newveterinarymedicinesregulationrisingtothechallenge AT mcalooncatherinei newveterinarymedicinesregulationrisingtothechallenge |